Ocugen

Ocugen’s 2027 Readout and a $255 Million Licensing Ceiling Are Two Very Different Kinds of Promise

angelina -

Ocugen Puts a Date on the Calendar, but 2027 Data Still Carries the Weight

kashif hafeez -

Ocugen Rewrites Phase 3 Yardstick as Cash Questions Loom Over 2027 Readout

angelina -

Ocugen’s 2027 BLA Target Confirmed as Shareholders Face a Long Wait and a Dilution Vote

angelina -

Ocugen’s 250-Million-Share Request Puts the 2027 Data Gap in Sharp Relief

Ocugen’s Global Push Gains Shape as Investors Wait on Funding Vote and Phase 3 Data

kashif hafeez -

Ocugen’s October Gauntlet: A Bahamian Green Light, a Packed Conference Slate, and the Overhang of a Share Vote

Ocugen Heads to Munich With a $10 Target — and a Shareholder Quorum Still Missing

kashif hafeez -

Ocugen’s Long Game: A Phase 3 Enrollment, a Regulatory Green Light, and a Market That Won’t Wait

Ocugen CEO Offloads 525,991 Shares Under Pre-Set Plan as Stock Hovers Near 52-Week Low

Brett Shapiro -

Ocugen’s 2027 Data Crossroads: New Leadership, Fresh Capital, and a Binary Bet on Two Trials

Ocugen’s Insider Buy Sends a Quiet Signal as Clinical Catalysts Loom

kashif hafeez -

Ocugen’s Countdown to 2027: Regulatory Path Clears as Cash Runway Extends, but Stock Remains Stuck in Neutral

Brett Shapiro -

Ocugen’s Gene-Therapy Pipeline: Three BLAs, One Platform, and a 670% Analyst Gap

Brett Shapiro -

Ocugen: Insider Buying Signals Confidence as Short Sellers Circle and Pipeline Nears Critical Data

1234Page 1 of 4